Pancreatic Cancer Research

ResearcherNanjing University of Chinese MedicineActive in the last 2 years

Kan Ding

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8140-9259; OpenAlex author ID A5042363295, A5151723762. Sources: OpenAlex.

Their work

Papers
16 (first author 0, last author 14)
Trials
0
Grants
0
Labs led
1
Collaborators
24
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 2 papers · 2018: none · 2019: 2 papers · 2020: 3 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 3 papers

Papers 16

  1. Intratumoral Enterobacter hormaechei drives gemcitabine resistance in pancreatic cancer via cdd L-mediated drug inactivation. Last author DOI 10.1002/imt2.70126↗
  2. A sulfated pectin polysaccharide from Chrysanthemum morifolium induces ferroptosis in pancreatic cancer by stabilizing TFRC. Last author DOI 10.1016/j.carbpol.2026.125224↗
  3. Active fragment assembly strategy enabling fast discovery of KRAS inhibitors against pancreatic cancer cells. Co-author DOI 10.1016/j.ejmech.2026.118807↗
  4. A dual-target pectin-like polysaccharide LRP01B from Lamiophlomis rotata induces pancreatic cancer cell apoptosis in vitro and in vivo by causing mitochondrial… Last author DOI 10.1016/j.ijbiomac.2025.147227↗
  5. Src is a target molecule of mannose against pancreatic cancer cells growth in vitro & in vivo. Last author DOI 10.1093/glycob/cwad070↗
  6. Convergent Synthesis and Anti-Pancreatic Cancer Cell Growth Activity of a Highly Branched Heptadecasaccharide from Carthamus tinctorius. Last author DOI 10.1002/anie.202202554↗
  7. The structure elucidation of novel arabinogalactan LRP1-S2 against pancreatic cancer cells growth in vitro and in vivo. Last author DOI 10.1016/j.carbpol.2021.118172↗
  8. A pectin-like polysaccharide from Polygala tenuifolia inhibits pancreatic cancer cell growth in vitro and in vivo by inducing apoptosis and suppressing autopha… Last author DOI 10.1016/j.ijbiomac.2020.06.054↗
  9. Cordycepin inhibits pancreatic cancer cell growth in vitro and in vivo via targeting FGFR2 and blocking ERK signaling. Last author DOI 10.1016/s1875-5364(20)30041-8↗
  10. Corn silk crude polysaccharide exerts anti-pancreatic cancer activity by blocking the EGFR/PI3K/AKT/CREB signaling pathway. Last author DOI 10.1039/d0fo00403k↗
  11. HH1-1, a novel Galectin-3 inhibitor, exerts anti-pancreatic cancer activity by blocking Galectin-3/EGFR/AKT/FOXO3 signaling pathway. Last author DOI 10.1016/j.carbpol.2018.10.008↗
  12. Isolation and structural characterization of a pectin from Lycium ruthenicum Murr and its anti-pancreatic ductal adenocarcinoma cell activity. Last author DOI 10.1016/j.carbpol.2019.115104↗
  13. RN1, a novel galectin-3 inhibitor, inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways. Last author DOI 10.1038/onc.2016.306↗
  14. A Concise Synthesis of Three Branches Derived from Polysaccharide RN1 and Anti-Pancreatic Cancer Activity Study. Last author DOI 10.3390/polym9100536↗
  15. Structure of a polysaccharide from Gastrodia elata Bl., and oligosaccharides prepared thereof with anti-pancreatic cancer cell growth activities Last author DOI 10.1016/j.carbpol.2011.06.029↗
  16. Silencing of hHS6ST2 inhibits progression of pancreatic cancer through inhibition of Notch signalling. Co-author DOI 10.1042/bj20110297↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Fei He · 4 shared papers, 2019–2025 · strength 0.68
  2. Chenghao Shao · 5 shared papers, 2011–2026 · strength 0.63
  3. Jianhao Xie · 2 shared papers, 2023–2025 · strength 0.48
  4. Zixuan Wang · 1 shared paper, 2026 · strength 0.32
  5. Pengli Zhang · 1 shared paper, 2026 · strength 0.30
  6. Guoqin Xia · 1 shared paper, 2026 · strength 0.30
  7. Jun‐Feng Peng · 1 shared paper, 2026 · strength 0.29
  8. Ju‐Dong Li · 1 shared paper, 2026 · strength 0.29
  9. Ting Niu · 1 shared paper, 2026 · strength 0.29
  10. Hong Tao · 2 shared papers, 2020 · strength 0.29
  11. Deqin Cai · 2 shared papers, 2017–2022 · strength 0.23
  12. Yanli Yao · 2 shared papers, 2017–2019 · strength 0.18
  13. Xia Chen · 2 shared papers, 2011–2021 · strength 0.18
  14. Chaoyu Hu · 1 shared paper, 2022 · strength 0.15
  15. Shihai Zhang · 1 shared paper, 2019 · strength 0.14
  16. Youcheng Bian · 1 shared paper, 2020 · strength 0.13
  17. Hui Zeng · 1 shared paper, 2020 · strength 0.13
  18. Xueying Li · 1 shared paper, 2020 · strength 0.13
  19. L Zhang · 1 shared paper, 2017 · strength 0.07
  20. Peng Li · 1 shared paper, 2017 · strength 0.07
  21. Yi Qin · 1 shared paper, 2017 · strength 0.07
  22. Ling Zhou · 1 shared paper, 2011 · strength 0.03
  23. Ping Li · 1 shared paper, 2011 · strength 0.03
  24. Kai Song · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.